Latest TNF inhibitor Stories
Simponi (golimumab) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023 LONDON, March 26, 2015 /PRNewswire/ -- SummaryRheumatoid arthritis (RA) is a chronic
LONDON, March 26, 2015 /PRNewswire/ -- SummaryRheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints.
DALLAS, March 18, 2015 /PRNewswire/ -- RnRMarketResearch.com adds "Methotrexate (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023" market research report provides
- 22 abstracts further evaluate the safety, efficacy of HUMIRA in psoriatic arthritis and moderate to severe chronic plaque psoriasis and investigational use of HUMIRA for the treatment of moderate
-- Hungarian National Registry reports interim results following Inflectra therapy in 90 patients with Crohn's disease and ulcerative colitis BARCELONA and MADRID, Spain, Feb.
-- Major European markets can finally benefit from the availability of Inflectra following the patent expiry of reference product Remicade® (infliximab) LAKE FOREST, Ill., Feb.
CRANBURY, N.J., Feb.
FIRST OF SEVERAL PHASE 3 TRIALS TO REPORT RESULTS INDIANAPOLIS, Dec.
Sales of Biologics Will Contribute Approximately $2.3 Billion to the UC Market in 2023, According to Findings from Decision Resources Group BURLINGTON, Mass., Nov.
Presentations examine certain demographic and clinical disease characteristics that may be indicative of Cimzia® treatment response and remission for moderate to severe Crohn's disease ATLANTA,